Table 2. Comparison between the remission and non-remission groups of NAFLD from baseline to month 12.
| Baseline | Month 12 | Difference between baseline and month 12 | P | ||
|---|---|---|---|---|---|
| BMI, kg/m2 | |||||
| Remission group | 29.29 ± 3.30 | 28.04 ± 3.30 | −1.25 | <0.001 | |
| Non-remission group | 28.72 ± 3.30 | 28.50 ± 3.20 | −0.22 | ||
| WC, cm | |||||
| Remission group | 96.05 ± 7.99 | 92.13 ± 8.81 | −3.92 | <0.001 | |
| Non-remission group | 93.86 ± 8.20 | 93.59 ± 8.41 | −0.27 | ||
| SBP, mmHg | |||||
| Remission group | 123.74 ± 11.05 | 121.41 ± 11.06 | −2.33 | 0.539 | |
| Non-remission group | 125.46 ± 13.62 | 121.59 ± 12.14 | −3.87 | ||
| DBP, mmHg | |||||
| Remission group | 76.82 ± 9.51 | 75.44 ± 9.90 | −1.38 | 0.691 | |
| Non-remission group | 79.03 ± 10.21 | 76.89 ± 8.76 | −2.14 | ||
| AST, IU/L | |||||
| Remission group | 34.76 ± 16.21 | 30.09 ± 17.08 | −4.67 | 0.110 | |
| Non-remission group | 31.99 ± 13.75 | 33.28 ± 21.83 | 1.29 | ||
| ALT, IU/L | |||||
| Remission group | 41.88 ± 24.13 | 30.88 ± 26.91 | −11 | 0.020 | |
| Non-remission group | 38.84 ± 20.99 | 39.57 ± 30.77 | 0.73 | ||
| r-GTP, IU/L | |||||
| Remission group | 83.68 ± 198.8 | 67.32 ± 160.25 | −16.36 | 0.172 | |
| Non-remission group | 52.78 ± 60.49 | 49.11 ± 46.73 | −3.67 | ||
| Albumin, g/dL | |||||
| Remission group | 4.45 ± 0.25 | 4.49 ± 0.21 | 0.04 | 0.037 | |
| Non-remission group | 4.56 ± 0.24 | 4.49 ± 0.25 | −0.07 | ||
| TC, mg/dL | |||||
| Remission group | 197.50 ± 36.55 | 188.85 ± 43.73 | −8.65 | 0.995 | |
| Non-remission group | 199.88 ± 42.32 | 191.28 ± 38.74 | −8.6 | ||
| TG, mg/dL | |||||
| Remission group | 219.44 ± 211.67 | 156.53 ± 88.29 | −62.91 | 0.198 | |
| Non-remission group | 190.62 ± 207.98 | 176.93 ± 109.76 | −13.69 | ||
| HDL-C, mg/dL | |||||
| Remission group | 46.56 ± 12.80 | 51.29 ± 16.14 | 4.73 | 0.001 | |
| Non-remission group | 48.04 ± 10.82 | 48.08 ± 11.00 | 0.04 | ||
| FBS, mg/dL | |||||
| Remission group | 117.09 ± 46.73 | 111.5 ± 30.25 | −5.59 | 0.524 | |
| Non-remission group | 112.89 ± 28.06 | 110.53 ± 22.07 | −2.36 | ||
| HbA1c, % | |||||
| Remission group | 6.30 ± 1.17 | 6.10 ± 0.91 | −0.2 | 0.434 | |
| Non-remission group | 6.15 ± 1.19 | 6.05 ± 0.78 | −0.1 | ||
| Insulin, mIU/L | |||||
| Remission group | 13.74 ± 7.07 | 10.94 ± 5.84 | −2.8 | 0.035 | |
| Non-remission group | 12.48 ± 6.61 | 12.32 ± 7.56 | −0.16 | ||
| FF, %† | |||||
| Remission group | 17.51 ± 9.34 | 6.39 ± 3.87 | −11.12 | <0.001 | |
| Non-remission group | 17.25 ± 7.91 | 16.71 ± 8.34 | −0.54 | ||
| M2BPGi, COI | |||||
| Remission group | 0.73 ± 0.22 | 0.67 ± 0.25 | −0.06 | 0.330 | |
| Non-remission group | 0.68 ± 0.30 | 0.67 ± 0.27 | −0.01 | ||
| Liver fibrosis based on MRE | |||||
| Remission group | 2.08 ± 0.68 | 2.06 ± 0.68 | −0.02 | 0.178 | |
| Non-remission group | 2.15 ± 0.58 | 2.30 ± 0.52 | 0.15 | ||
Data are mean±standard-deviation values
Abbreviation: NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aminotransferase; ALT, alanine aminotransferase; r-GTP, gamma-glutamyl transpeptidase; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; FBS, fasting blood sugar; HbA1c, hemoglobin A1C; FF, fat fraction; M2BPGi, Mac-2 binding protein glycosylation isomer; COI, cutoff index; MRE, magnetic resonance elastography.